Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (56)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Lindauer, K.
Right arrow Articles by Kroemer, R. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lindauer, K.
Right arrow Articles by Kroemer, R. T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Protein Engineering, Vol. 14, No. 1, 27-37, January 2001
© 2001 Oxford University Press

Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation

Klaus Lindauer1, Thomas Loerting2, Klaus R. Liedl2 and Romano T. Kroemer1,3

1 Department of Chemistry, Queen Mary and Westfield College, University of London, Mile End Road, London E1 4NS, UK and 2 Institute of General, Inorganic and Theoretical Chemistry, University of Innsbruck, Innrain 52a, A-6020 Innsbruck, Austria

The structure of human Janus kinase 2 (JAK2) comprising the two C-terminal domains (JH1 and JH2) was predicted by application of homology modelling techniques. JH1 and JH2 represent the tyrosine kinase and tyrosine kinase-like domains, respectively, and are crucial for function and regulation of the protein. A comparison between the structures of the two domains is made and structural differences are highlighted. Prediction of the relative orientation of JH1 and JH2 was aided by a newly developed method for the detection of correlated amino acid mutations. Analysis of the interactions between the two domains led to a model for the regulatory effect of JH2 on JH1. The predictions are consistent with available experimental data on JAK2 or related proteins and provide an explanation for inhibition of JH1 tyrosine kinase activity by the adjacent JH2 domain.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
M. Funakoshi-Tago, K. Tago, K. Sumi, M. Abe, E. Aizu-Yokota, T. Oshio, Y. Sonoda, and T. Kasahara
The Acute Lymphoblastic Leukemia-associated JAK2 L611S Mutant Induces Tumorigenesis in Nude Mice
J. Biol. Chem., May 8, 2009; 284(19): 12680 - 12690.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. L. Levine and D. G. Gilliland
Myeloproliferative disorders
Blood, September 15, 2008; 112(6): 2190 - 2198.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Gakovic, J. Ragimbeau, V. Francois, S. N. Constantinescu, and S. Pellegrini
The Stat3-activating Tyk2 V678F Mutant Does Not Up-regulate Signaling through the Type I Interferon Receptor but Confers Ligand Hypersensitivity to a Homodimeric Receptor
J. Biol. Chem., July 4, 2008; 283(27): 18522 - 18529.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Dusa, J. Staerk, J. Elliott, C. Pecquet, H. A. Poirel, J. A. Johnston, and S. N. Constantinescu
Substitution of Pseudokinase Domain Residue Val-617 by Large Non-polar Amino Acids Causes Activation of JAK2
J. Biol. Chem., May 9, 2008; 283(19): 12941 - 12948.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
E. Flex, V. Petrangeli, L. Stella, S. Chiaretti, T. Hornakova, L. Knoops, C. Ariola, V. Fodale, E. Clappier, F. Paoloni, et al.
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia
J. Exp. Med., April 14, 2008; 205(4): 751 - 758.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. Wernig, J. R. Gonneville, B. J. Crowley, M. S. Rodrigues, M. M. Reddy, H. E. Hudon, C. Walz, A. Reiter, K. Podar, Y. Royer, et al.
The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes
Blood, April 1, 2008; 111(7): 3751 - 3759.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
X. Lu, L. J.-S. Huang, and H. F. Lodish
Dimerization by a Cytokine Receptor Is Necessary for Constitutive Activation of JAK2V617F
J. Biol. Chem., February 29, 2008; 283(9): 5258 - 5266.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. B. Hookham, J. Elliott, Y. Suessmuth, J. Staerk, A. C. Ward, W. Vainchenker, M. J. Percy, M. F. McMullin, S. N. Constantinescu, and J. A. Johnston
The myeloproliferative disorder associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3
Blood, June 1, 2007; 109(11): 4924 - 4929.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
E. C. Wolstencroft, K. Hanlon, L. W. Harries, G. R. Standen, A. Sternberg, and S. Ellard
Development of a Quantitative Real-Time Polymerase Chain Reaction Assay for the Detection of the JAK2 V617F Mutation
J. Mol. Diagn., February 1, 2007; 9(1): 42 - 46.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
R. Skoda
The Genetic Basis of Myeloproliferative Disorders
Hematology, January 1, 2007; 2007(1): 1 - 10.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. G.P. Bumm, C. Elsea, A. S. Corbin, M. Loriaux, D. Sherbenou, L. Wood, J. Deininger, R. T. Silver, B. J. Druker, and M. W.N. Deininger
Characterization of Murine JAK2V617F-Positive Myeloproliferative Disease
Cancer Res., December 1, 2006; 66(23): 11156 - 11165.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
I. S. Lucet, E. Fantino, M. Styles, R. Bamert, O. Patel, S. E. Broughton, M. Walter, C. J. Burns, H. Treutlein, A. F. Wilks, et al.
The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor
Blood, January 1, 2006; 107(1): 176 - 183.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
X. Lu, R. Levine, W. Tong, G. Wernig, Y. Pikman, S. Zarnegar, D. G. Gilliland, and H. Lodish
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation
PNAS, December 27, 2005; 102(52): 18962 - 18967.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Staerk, A. Kallin, J.-B. Demoulin, W. Vainchenker, and S. N. Constantinescu
JAK1 and Tyk2 Activation by the Homologous Polycythemia Vera JAK2 V617F Mutation: CROSS-TALK WITH IGF1 RECEPTOR
J. Biol. Chem., December 23, 2005; 280(51): 41893 - 41899.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
K. He, K. Loesch, J. W. Cowan, X. Li, L. Deng, X. Wang, J. Jiang, and S. J. Frank
Janus Kinase 2 Enhances the Stability of the Mature Growth Hormone Receptor
Endocrinology, November 1, 2005; 146(11): 4755 - 4765.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. V. Jones, S. Kreil, K. Zoi, K. Waghorn, C. Curtis, L. Zhang, J. Score, R. Seear, A. J. Chase, F. H. Grand, et al.
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
Blood, September 15, 2005; 106(6): 2162 - 2168.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
M. Pesu, J. O'Shea, L. Hennighausen, and O. Silvennoinen
Identification of an Acquired Mutation in Jak2 Provides Molecular Insights into the Pathogenesis of Myeloproliferative Disorders
Mol. Interv., August 1, 2005; 5(4): 211 - 215.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
A. Tefferi and D. G. Gilliland
The JAK2V617F Tyrosine Kinase Mutation in Myeloproliferative Disorders: Status Report and Immediate Implications for Disease Classification and Diagnosis
Mayo Clin. Proc., July 1, 2005; 80(7): 947 - 958.
[Abstract] [PDF]

Home page
 BloodHome page
K. Kaushansky
On the molecular origins of the chronic myeloproliferative disorders: it all makes sense
Blood, June 1, 2005; 105(11): 4187 - 4190.
[Full Text] [PDF]

Home page
 ASH Education BookHome page
W. Vainchenker and S. N. Constantinescu
A Unique Activating Mutation in JAK2 (V617F) Is at the Origin of Polycythemia Vera and Allows a New Classification of Myeloproliferative Diseases
Hematology, January 1, 2005; 2005(1): 195 - 200.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
K. Kaushansky
On the Molecular Origins of the Chronic Myeloproliferative Disorders: It All Makes Sense
Hematology, January 1, 2005; 2005(1): 533 - 537.
[Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
L. S. Argetsinger, J.-L. K. Kouadio, H. Steen, A. Stensballe, O. N. Jensen, and C. Carter-Su
Autophosphorylation of JAK2 on Tyrosines 221 and 570 Regulates Its Activity
Mol. Cell. Biol., June 1, 2004; 24(11): 4955 - 4967.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
K. He, X. Wang, J. Jiang, R. Guan, K. E. Bernstein, P. P. Sayeski, and S. J. Frank
Janus Kinase 2 Determinants for Growth Hormone Receptor Association, Surface Assembly, and Signaling
Mol. Endocrinol., November 1, 2003; 17(11): 2211 - 2227.
[Abstract] [Full Text] [PDF]

Home page
 Protein Eng Des SelHome page
F. Giordanetto and R. T. Kroemer
A three-dimensional model of Suppressor Of Cytokine Signalling 1 (SOCS-1)
Protein Eng. Des. Sel., February 1, 2003; 16(2): 115 - 124.
[Abstract] [Full Text] [PDF]

Home page
 Protein Eng Des SelHome page
F. Giordanetto and R. T. Kroemer
Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7
Protein Eng. Des. Sel., September 1, 2002; 15(9): 727 - 737.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.